On Friday, Echelon Capital Markets initiated coverage on Cognetivity Neurosciences (CSE: CGN) with a speculative buy rating and C$0.85 12-month price target. This is the first analyst coverage on the name. Stefan Quenneville headlines, “You Cannot Afford to Forget this Company; AI-Powered Test Could Be a Game-Changer in Alzheimer’s Detection.”
Cognetivity Neurosciences is a telehealth company that helps detect the early signs of cognitive decline using artificial intelligence. The company has developed a platform that takes 5 minutes to determine the patient’s cognitive ability, which it then monitors over time.
The cognitive assessment and training market is currently a U$3.2 billion market and is estimates to be growing at a GAGR of 29%. Cognetivity Neurosciences is looking to take market share in two specific categories: primary care settings, “wherein CGN is focused on having clinicians use this as an assessment in the clinic and at-home,” while the other market is a consumer use case.
Echelon believes that in-clinic sales are a U$250 million market while at-home monitoring is a U$1.2 billion market.
They believe that revenue sharing via a 75:25 structure will incentivize clinicians to use their product which will help drive early adoption. Additionally, they believe that the company is potentially well-positioned to secure contracts with public and private payors, “given the increasing recognition of healthcare cost savings attainable through early detection of disease.”
Below you can see Echelon’s revenue break down going into 2026.
FULL DISCLOSURE: Cognetivity Neurosciences Ltd is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Cognetivity Neurosciences Ltd on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.